RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy

A new era of early cancer detection with blood test may change cancer screening paradigms

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

New era of early cancer detection blood tests on the horizon

Hyperthermic intraperitoneal chemo for locally advanced colon cancer